<p>LENZ Therapeutics, Inc.（纳斯达克代码：LENZ - 获取免费报告）在周五的交易中交易量强劲，此前 Raymond James Financial 将该股票的目标价从 39.00 美元上调至 40.00 美元。Raymond James Financial 目前对该股票的评级为跑赢大盘。在交易中交易了 415,673 股，较前一交易日的 239,685 股增加了 73%。该股票最后交易价格为 30.08 美元，之前收盘价为 29.77 美元。</p>
<p>其他一些券商也最近对 LENZ 发表了评论。HC Wainwright 在周一的研究报告中重申了 “买入” 评级，并将 LENZ Therapeutics 的目标价上调至 48.00 美元（之前为 38.00 美元）。花旗集团在周四的报告中重新发布了 “买入” 评级，并将 LENZ Therapeutics 的目标价上调至 49.00 美元（之前为 45.00 美元）。最后，Piper Sandler 在 4 月 14 日的报告中开始覆盖 LENZ Therapeutics。他们对该公司的评级为 “增持”，目标价为 51.00 美元。五位投资分析师对该股票给予了买入评级，一位分析师给予了强烈买入评级。根据 MarketBeat 的数据，该股票的共识评级为 “买入”，共识目标价为 49.60 美元。</p>
<p>获取 <strong>LENZ Therapeutics</strong> 的提醒：</p>
<p><strong>查看我们关于 LENZ Therapeutics 的最新研究报告</strong></p>
<h2>机构投资者对 LENZ Therapeutics 的看法</h2>
<p>对冲基金和其他机构投资者最近买入和卖出了该公司的股票。KLP Kapitalforvaltning AS 在第四季度收购了 LENZ Therapeutics 的新股份，价值 46,000 美元。Tower Research Capital LLC TRC 在第四季度将其在 LENZ Therapeutics 的持股增加了 162.3%。Tower Research Capital LLC TRC 现在拥有 1,860 股该公司的股票，价值 54,000 美元，此前在上个季度购买了 1,151 股。Virtus ETF Advisers LLC 在第四季度购买了 LENZ Therapeutics 的新头寸，价值 67,000 美元。Banque Transatlantique SA 在第一季度购买了 LENZ Therapeutics 的新头寸，价值 119,000 美元。最后，GAMMA Investing LLC 在第一季度将其在 LENZ Therapeutics 的头寸增加了 5,254.1%。GAMMA Investing LLC 现在拥有 5,836 股该公司的股票，价值 150,000 美元，此前在上个季度购买了 5,727 股。54.32% 的股票由机构投资者和对冲基金持有。</p>
<h2>LENZ Therapeutics 股票表现</h2>
<p>该股票的市值为 8.4816 亿美元，市盈率为-15.92，贝塔值为 0.42。该股票的 50 日简单移动平均线为 30.99 美元，200 日简单移动平均线为 26.90 美元。</p>
<p>LENZ Therapeutics（纳斯达克代码：LENZ - 获取免费报告）最近在 7 月 30 日（星期三）公布了季度财报。该公司报告季度每股收益为（0.53 美元），超出分析师共识预期的（0.58 美元）0.05 美元。该公司在本季度的收入为 500 万美元，而共识预期为 500 万美元。股票分析师预测 LENZ Therapeutics, Inc.在本年度的每股收益将为-2.18 美元。</p>
<h2>关于 LENZ Therapeutics</h2>
<p>（获取免费报告）</p>
<p>LENZ Therapeutics, Inc.是一家生物制药公司，专注于开发和商业化改善美国视力的疗法。其产品候选包括 LNZ100 和 LNZ101，目前正在进行治疗老花眼的第三阶段临床试验。该公司总部位于加利福尼亚州德尔玛。</p>
<h2>特色文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 LENZ Therapeutics</li>
<li>关于 Markup 计算器</li>
<li>Rocket Lab 下周报告：投资者需要知道的事项</li>
<li>复利及其在投资中的重要性</li>
<li>苹果股票：大盈利，小波动——是时候买入了吗？</li>
<li>Russell 2000 指数，投资者如何利用它进行盈利交易</li>
<li>亚马逊的收益：接下来会发生什么以及如何应对</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 LENZ Therapeutics 吗？</h2>
<p>在考虑 LENZ Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议现在买入，以便在更广泛的市场注意到之前……而 LENZ Therapeutics 并不在名单上。</p>
<p>虽然 LENZ Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得买入。</p>
<p>在这里查看这五只股票</p>

LENZ

<p>LENZ Therapeutics（纳斯达克代码：LENZ）在 Raymond James Financial 将其目标股价从 39.00 美元上调至 40.00 美元并维持 “跑赢大盘” 评级后，交易量激增。该股票交易了 415,673 股，比前一交易日增加了 73%。其他券商，包括 HC Wainwright 和花旗集团，也上调了他们的目标股价，市场共识评级显示为买入。该股票的市值为 8.4816 亿美元，报告的季度每股收益为（0.53 美元），超出预期。LENZ 专注于开发视力改善疗法，目前产品处于第三阶段临床试验中</p>

<p>Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) saw strong trading volume on Friday after Raymond James Financial raised their price target on the stock from $39.00 to $40.00. Raymond James Financial currently has an outperform rating on the stock. 415,673 shares were traded during trading, an increase of 73% from the previous session's volume of 239,685 shares.The stock last traded at $30.08 and had previously closed at $29.77.</p>
<div class="lb-trans"><p>LENZ Therapeutics, Inc.（纳斯达克代码：LENZ - 获取免费报告）在周五的交易中交易量强劲，此前 Raymond James Financial 将该股票的目标价从 39.00 美元上调至 40.00 美元。Raymond James Financial 目前对该股票的评级为跑赢大盘。在交易中交易了 415,673 股，较前一交易日的 239,685 股增加了 73%。该股票最后交易价格为 30.08 美元，之前收盘价为 29.77 美元。</p>
</div><p>A number of other brokerages also recently commented on LENZ. HC Wainwright reiterated a &#34;buy&#34; rating and issued a $48.00 price objective (up previously from $38.00) on shares of LENZ Therapeutics in a research report on Monday. Citigroup reissued a &#34;buy&#34; rating and issued a $49.00 target price (up from $45.00) on shares of LENZ Therapeutics in a report on Thursday. Finally, Piper Sandler initiated coverage on LENZ Therapeutics in a report on Monday, April 14th. They issued an &#34;overweight&#34; rating and a $51.00 target price for the company. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of &#34;Buy&#34; and a consensus target price of $49.60.</p>
<div class="lb-trans"><p>其他一些券商也最近对 LENZ 发表了评论。HC Wainwright 在周一的研究报告中重申了 “买入” 评级，并将 LENZ Therapeutics 的目标价上调至 48.00 美元（之前为 38.00 美元）。花旗集团在周四的报告中重新发布了 “买入” 评级，并将 LENZ Therapeutics 的目标价上调至 49.00 美元（之前为 45.00 美元）。最后，Piper Sandler 在 4 月 14 日的报告中开始覆盖 LENZ Therapeutics。他们对该公司的评级为 “增持”，目标价为 51.00 美元。五位投资分析师对该股票给予了买入评级，一位分析师给予了强烈买入评级。根据 MarketBeat 的数据，该股票的共识评级为 “买入”，共识目标价为 49.60 美元。</p>
</div><p>Get <strong>LENZ Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>LENZ Therapeutics</strong> 的提醒：</p>
</div><p><strong>View Our Latest Research Report on LENZ Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 LENZ Therapeutics 的最新研究报告</strong></p>
</div><h2>Institutional Investors Weigh In On LENZ Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 LENZ Therapeutics 的看法</h2>
</div><p>Hedge funds and other institutional investors have recently bought and sold shares of the business. KLP Kapitalforvaltning AS acquired a new stake in LENZ Therapeutics during the 4th quarter valued at $46,000. Tower Research Capital LLC TRC increased its holdings in LENZ Therapeutics by 162.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,860 shares of the company's stock valued at $54,000 after purchasing an additional 1,151 shares in the last quarter. Virtus ETF Advisers LLC bought a new position in LENZ Therapeutics in the 4th quarter valued at $67,000. Banque Transatlantique SA bought a new position in LENZ Therapeutics in the 1st quarter valued at $119,000. Finally, GAMMA Investing LLC boosted its position in LENZ Therapeutics by 5,254.1% in the 1st quarter. GAMMA Investing LLC now owns 5,836 shares of the company's stock valued at $150,000 after buying an additional 5,727 shares during the last quarter. 54.32% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近买入和卖出了该公司的股票。KLP Kapitalforvaltning AS 在第四季度收购了 LENZ Therapeutics 的新股份，价值 46,000 美元。Tower Research Capital LLC TRC 在第四季度将其在 LENZ Therapeutics 的持股增加了 162.3%。Tower Research Capital LLC TRC 现在拥有 1,860 股该公司的股票，价值 54,000 美元，此前在上个季度购买了 1,151 股。Virtus ETF Advisers LLC 在第四季度购买了 LENZ Therapeutics 的新头寸，价值 67,000 美元。Banque Transatlantique SA 在第一季度购买了 LENZ Therapeutics 的新头寸，价值 119,000 美元。最后，GAMMA Investing LLC 在第一季度将其在 LENZ Therapeutics 的头寸增加了 5,254.1%。GAMMA Investing LLC 现在拥有 5,836 股该公司的股票，价值 150,000 美元，此前在上个季度购买了 5,727 股。54.32% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>LENZ Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>LENZ Therapeutics 股票表现</h2>
</div><p>The stock has a market capitalization of $848.16 million, a P/E ratio of -15.92 and a beta of 0.42. The stock has a 50-day simple moving average of $30.99 and a 200 day simple moving average of $26.90.</p>
<div class="lb-trans"><p>该股票的市值为 8.4816 亿美元，市盈率为-15.92，贝塔值为 0.42。该股票的 50 日简单移动平均线为 30.99 美元，200 日简单移动平均线为 26.90 美元。</p>
</div><p>LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The company reported ($0.53) EPS for the quarter, beating analysts' consensus estimates of ($0.58) by $0.05. The firm had revenue of $5.00 million during the quarter, compared to the consensus estimate of $5.00 million. Equities analysts predict that LENZ Therapeutics, Inc. will post -2.18 earnings per share for the current year.</p>
<div class="lb-trans"><p>LENZ Therapeutics（纳斯达克代码：LENZ - 获取免费报告）最近在 7 月 30 日（星期三）公布了季度财报。该公司报告季度每股收益为（0.53 美元），超出分析师共识预期的（0.58 美元）0.05 美元。该公司在本季度的收入为 500 万美元，而共识预期为 500 万美元。股票分析师预测 LENZ Therapeutics, Inc.在本年度的每股收益将为-2.18 美元。</p>
</div><h2>About LENZ Therapeutics</h2>
<div class="lb-trans"><h2>关于 LENZ Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.</p>
<div class="lb-trans"><p>LENZ Therapeutics, Inc.是一家生物制药公司，专注于开发和商业化改善美国视力的疗法。其产品候选包括 LNZ100 和 LNZ101，目前正在进行治疗老花眼的第三阶段临床试验。该公司总部位于加利福尼亚州德尔玛。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than LENZ Therapeutics</li>
<li>About the Markup Calculator</li>
<li>Rocket Lab Reports Next Week: Here’s What Investors Should Know</li>
<li>Compound Interest and Why It Matters When Investing</li>
<li>Apple Stock: Big Earnings, Small Move—Time to Buy?</li>
<li>Russell 2000 Index, How Investors Use it For Profitable Trading</li>
<li>Amazon's Earnings: What Comes Next and How to Play It</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 LENZ Therapeutics</li>
<li>关于 Markup 计算器</li>
<li>Rocket Lab 下周报告：投资者需要知道的事项</li>
<li>复利及其在投资中的重要性</li>
<li>苹果股票：大盈利，小波动——是时候买入了吗？</li>
<li>Russell 2000 指数，投资者如何利用它进行盈利交易</li>
<li>亚马逊的收益：接下来会发生什么以及如何应对</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in LENZ Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 LENZ Therapeutics 吗？</h2>
</div><p>Before you consider LENZ Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 LENZ Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENZ Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议现在买入，以便在更广泛的市场注意到之前……而 LENZ Therapeutics 并不在名单上。</p>
</div><p>While LENZ Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 LENZ Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得买入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

LENZ Therapeutics（NASDAQ:LENZ）因分析师上调评级而交易量显著增加